BioStock: Sensidose’s founder talks about the company’s journey

The idea for Sensidose’s treatment strategy came about already in the mid-1990s when professors Sten-Magnus Aquilonius and Christer Nyström realized that it would be possible to personalise Parkinson’s treatment with microtablets. Today, the company’s drug Flexilev is available on the Scandinavian market and in the near future also in more countries. BioStock had a chat with Sten-Magnus Aquilonius about his research and Sensidose’s journey from start to now.

Read the full article at biostock.se:

https://www.biostock.se/en/2022/09/sensidoses-founder-talks-about-the-companys-journey/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se